CryoLife, Inc. (NYSE: CRY) is one we generally consider as devices rather than true biohealth, but it often falls under both based on its history. The company has had a questionable track record and…
The fight against melanoma just got a new weapon after a drug called Yervoy, or ipilimumab, was given FDA approval for late-stage metastatic melanoma. The approval is a win for Bristol-Myers Squibb Company (NYSE: BMY)…
Prana Biotechnology Ltd. (NASDAQ: PRAN) may have left shareholders feeling like they got the wool pulled over their eyes this week. The company’s ADRs surged on reports that an article highlighted very positive cognitive…
It was not that long ago that Walgreen Co. (NYSE: WAG) sold off its PBM unit to Catalyst Health Solutions, Inc. (NASDAQ: CHSI). The deal was valued around $525 million, and now Walgreen has…
It is time for “The Daily Dividend” and we have an interesting call ahead. How long has it been that Amgen Inc. (NASDAQ: AMGN) has been touted as a “Should Be” dividend stock? Too long. …
Xoma Ltd. (NASDAQ: XOMA) is getting crushed this morning on news that its potential Type-2 diabetes drug failed to lower blood sugar levels. The news is bad, but there are a few things here which…
It’s the BioHeath Daily for key developments in drugs, biotech, and medical developments. Prana Biotechnology Ltd. (NASDAQ: PRAN) is often overlooked here in the U.S. as it has such a small market cap. That…
There are several ways to measure what many experts describe as a shortage of physicians in some parts of the United States. The first is the ratio of doctors per thousand people. America’s rank…
The US Food and Drug Administration and Johnson & Johnson (NYSE: JNJ) have agreed to a consent decree under which the agency will monitor manufacturing processes at three plants operated by J&J’s McNeil Consumer…
As you would expect now that Benlysta has been approved as the first Lupus treatment in more than 50 years, some investors are wondering and perhaps hoping that Human Genome Sciences, Inc. (NASDAQ: HGSI)…
The upcoming HCA Holdings Inc. (NYSE: HCA) IPO is turning out to be better than what we had expected. The 124 million shares have been expected to price between $27 and $30 per share…
Catalyst Health Solutions, Inc. (NASDAQ: CHSI) is not as well known in American healthcare as it is about to be. The pharmacy benefit management company has just signed a pact to acquire the PBM…
Investors love huge biotech opportunities for growth. Investors also love to get paid in the form of dividends. Unfortunately, the terms “dividend” and “biotech” never match up. While some hopes have been out there…
While the courts and the Congress continue to fight over the health-care reform law, known as the Affordable Care Act or ACA, insurers are looking forward to as many as 16 million new customers…
It has finally happened. Genzyme Corporation (NASDAQ: GENZ) is being acquired by Sanofi-Aventis (NYSE: SNY). The deal should trade at a premium to the $74.00 cash component due to what is called the Contingent…